FAQs about TIGLUTIK (riluzole)
What is TIGLUTIK?
TIGLUTIK is the first and only easy-to-swallow oral suspension alternative to riluzole tablets for the treatment of amyotrophic lateral sclerosis (ALS).1,2
How do my patients take TIGLUTIK?
Patients take 10 mL of oral suspension TIGLUTIK twice a day. This dose includes the same 50 mg found in a riluzole tablet.1,3
How is TIGLUTIK supplied to my patients?
TIGLUTIK 50 mg/10 mL (5 mg/mL) oral suspension is supplied in amber glass bottles closed with child-resistant, tamper-evident screw caps. Each bottle contains 300 mL of oral suspension and is intended for multidose use. TIGLUTIK is supplied in a carton containing two 300 mL bottles, two plastic 10 mL oral dispensers (syringes), two syringe bottle adapters, and two syringe tip caps.1
Can my patient take TIGLUTIK if she is pregnant?
There are no studies of riluzole, the active ingredient in TIGLUTIK, in pregnant women, and case reports have been inadequate to inform on the drug-associated risk. Based on animal data, women should be advised of a possible risk to the fetus associated with use of TIGLUTIK during pregnancy.1
Can my patient breastfeed while she is taking TIGLUTIK?
It is not known if riluzole, the active ingredient in TIGLUTIK, is excreted in human milk. Riluzole or its metabolites have been detected in the milk of lactating rats. Women should be advised that many drugs are excreted in human milk and that the potential for serious adverse reactions in nursing infants from riluzole is unknown.1
Does TIGLUTIK have any contraindications?
TIGLUTIK is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components (anaphylaxis has occurred).1
- TIGLUTIK (riluzole) [package insert]. Berwyn, PA: ITF Pharma; September 2018.
- Keating GM. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Ther Perspect. 2016;32(7):282-286.
- Rilutek (riluzole) [package insert]. Cary, NC: Covis Pharmaceuticals, Inc.; April 2016.